CaSE are delighted to welcome Richmond Pharmacology as new organisational members.
New research institute joins the Campaign for Science and Engineering
05 Sep 2018
Commenting on today’s announcement, Dr Sarah Main, Executive Director of the Campaign for the Science and Engineering, said:
“We are extremely pleased to welcome Richmond Pharmacology as an organisational member of CaSE. As we look ahead to the Government’s spending review this Autumn, we will work with the institute along with our wider membership to convey a strong, united case for sustained investment in science and engineering. We look forward to working with Richmond Pharmacology, who play a crucial role in the health of the UK life sciences sector.”
Dr Jorg Taubel, Chief Executive at Richmond Pharmacology:
“We are delighted to have become a member of CaSE. We strongly believe that the development of science and engineering skills in the UK is integral to future economic growth. During uncertain times such as these, organisations such as CaSE play a valuable role in pushing for continued industry access to highly trained and well educated staff from both home and abroad.”
Richmond Pharmacology Ltd is a research institute with a global reputation for excellence in clinical research. Founded in 2001, we are the leading Early Phase full-service Contract Research Organisation (CRO) in the country. Richmond’s clinical trials are often complex and cutting edge and conducted in important disease areas, including oncology and amyloidosis. Currently based at the Guy’s Drug Research Unit at Guy’s and St Thomas’s Hospital in central London, we have worked with NHS partners to conduct between 15 and 20 clinical trials per year, amounting to over 300 studies in London since 2001.
As a fully MHRA-accredited CRO, our 100 skilled staff carry out clinical studies to the highest ethical and medical standards. Our interaction with healthy research volunteers, patients, patient groups, clinical and academic specialists in their respective fields, ensures our research meets the highest regulatory, scientific and ethical requirements. Richmond is also a good corporate citizen, funding academic research and publications, creating jobs in the local community and contributing to its stakeholders and charities. Over the last 15 years we have made a net contribution of 7% of our cumulative turnover – over £100m – to the NHS. The company is also a prominent stakeholder which actively and very successfully promotes UK life sciences globally.
CaSE is pleased to welcome Elsevier into its membership. Elsevier have supported CaSE’s work for many years, and we are delighted they have joined us as members.
Alicia Greated will be the new Executive Director of the Campaign for Science and Engineering (CaSE) from early April 2024.
After 10 years as Executive Director of the Campaign for Science and Engineering, Professor Sarah Main is leaving the role at the end of November 2023.
The Campaign for Science and Engineering (CaSE) is pleased to welcome LifeArc to its membership.